MoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimab

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA.